Non Erosive Reflux DiseaseNCT02575287
Minimal Injuries From Esophagus Detected by Optical Enhancement System™ Associated to Optical Magnification HD Scopes
An observational study of Non Erosive Reflux Disease and GERD, run by Instituto Ecuatoriano de Enfermedades Digestivas at 1 site in Ecuador.
Trial summary
White light endoscopy remains the gold standard technique to evaluate gastrointestinal tract. Gastroesophageal Reflux Disease (GERD) is defined as presence of reflux symptoms (heartburn and regurgitation) associated or not with lesions in esophageal mucosa. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non Erosive Reflux Disease, GERD
- What is being tested?
- Optical Enhancement, Optical Enhancement with optical magnification and Optical magnification without Optical enhancement
- Type of treatment
- Medical device
- How many people
- 100 participants
- Where
- 1 siteEcuador
- Study dates
- Sep 2015to Jan 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients that had reflux symptoms (heartburn and regurgitation) and 8 or more points at the Spanish version of GERD questionnaire validated by Zavala-González et al. underwent an upper videoendoscopy using initially high definition white light and then digital chromoendoscopy (I-Scan™) in the three different image algorithms. If the esophagus was normal and no changes were seen by these two techniques, they were considered as NERD patients and a pH-impedanciometry was performed as gold standard study, in order to diagnosis reflux disease. We considered a GERD diagnosis with more than 73 episodes of reflux in 24 hours or acid exposure time abnormal with ph<4 measured in more than 4,2%of the time over 24 hours.
Who may be able to join
- Above 18 years old patients
- Who agree to participate in the study
- Patients with reflux symptoms (heartburn and regurgitation), with8 or more points at the GERD questionnaire and no evidence of ulcerative esophagitis, esophageal strictures, Barrett's esophagus or any erosive sign according to Los Angeles classification (Grade A to D) in the upper endoscopy using white light nor I-Scan™
Who cannot join
- Patients with ulcerative esophagitis, esophageal strictures, Barrett's esophagus or any erosive sign according to Los Angeles classification (Grade A to D)
- Patients with medical history of any kind of esophagitis (including actinic, caustic or eosinophilic), achalasia.
- Esophageal varices
- Patients with evidence of cancer or mass lesion in the esophagus
- Protons bump inhibitor consumption for at least 3 weeks before endoscopy
- Inability to discontinue non steroidal anti-inflammatory drugs or aspirin prior to the study
Show all 10Show fewer
- Severe uncontrolled coagulopathy
- Gastric lesions (ulcer, polyp, cancer), severe gastroparesis
- Prior history of esophageal or gastric surgery.
- Pregnancy and lactation
Trial locations and contacts
1 site in 1 country.
Ecuador1 site
Ecuadorian Institute of Digestive Diseases, Omnihospital
Guayaquil, Guayas, 090505
About this study
Official title: Mucosal and Minimal Injuries Detected Through Digital Chromoendoscopy Using Optical Enhancement System™ Associated to High Definition Plus Optical Magnification in Non Erosive Gastroesophageal Reflux Disease
White light endoscopy remains the gold standard technique to evaluate gastrointestinal tract. Gastroesophageal Reflux Disease (GERD) is defined as presence of reflux symptoms (heartburn and regurgitation) associated or not with lesions in esophageal mucosa. Based on findings at videoendoscopy GERD patients can have a complicated reflux disease (erosive esophagitis) or not and be considered as a non erosive reflux disease (NERD). 60% of GERD patients have normal endoscopy (NERD) and requires further studies to achieve a definitive diagnosis. Based on this fact is that the study will be focus on NERD patients.
Recently an image-enhanced endoscopic technology using a pre-processor band-limited light called Optical Enhancement system (OE system™), was developed (Pentax Medical). This new technology combines digital signal processing with optical filters that limit the spectral characteristics of the illumination light. The new innovated optical filters achieve higher overall transmittance by connecting the peaks of the hemoglobin absorption spectrum (415 nm, 540 nm and 570 nm) creating a continuous wavelength spectrum. There are two modes with different OE filters (Mode 1 and Mode 2). Mode 1 is designed to improve visualization of microvessels with a sufficient amount of light, and Mode 2 is designed to improve contrast of white-light observation by bringing the color tone of the overall image closer to that of natural color.
In addition, new scopes has been developed which combines high definition images with optical magnification called Magniview™. These scopes increase the image up to 136 times with a better quality of image than standard scopes without optical zoom. Sharma et al. evaluated esophageal changes in NERD patients using a similar pre-processor filter called Narrow Band Imaging (NBI). They found that a significantly higher proportion of patients with NERD had an increased number, dilation and tortuosity of the microscopic intrapapillary capillary loops (IPCLs), and were considered the best predictors for diagnosing NERD. They used optical chromoendoscopy technology (NBI) associated to magnification scopes (Olympus GIF Q240Z, 115x), but they did not evaluated if the contribution with this technology to the observations found in GERD patients were as a result of the NBI or the magnification scopes. The investigators opinion is that chromoendoscopy is useful but is the magnification what makes up the difference.
Read the detailed description
Sharma et al. described in detail the changes of the intrapapillary capillaries seen with reflux inflammation. In the normal esophageal mucosa, submucosa all vessels are connected to the arborescent vascular network. Intrapapillary capillaries arise from the fourth branch of the arborescent vessels into the epithelial papillae and form single loops called IPCLs. It has been shown that IPCLs dilate and elongate along with an increase in the number and density of arborescent vessels in mucosal cancer. These changes are similar to those observed in inflammation.
Estimated enrollment: 100 patients (NERD group: 50 patients and control group: 50 patients)
Study design: This is an observational and analytical cross-section, population - based survey study, with prospective case collection, non-randomized and simple blind, performed in a Tertiary Academic Center.
Study Design
- Allocation: Non randomized, simple blind
- Endpoint Classification: Efficacy
- Intervention Model: Non interventional
- Primary Purpose: Diagnosis
Setting: Instituto Ecuatoriano de Enfermedades Digestivas (IECED), OmniHospital Academic Tertiary Center. We will include patients from September 2015 to November 2015. Patients will be recruited from the gastroenterology unit (IECED). The study protocol and consent form has been approved by the IRB and will be conducted according to the declaration of Helsinki. Patients will sign an informed consent and answer a questionnaire that includes constitutional data (sex, age, weight (Kg), height (m), BMI (Kg/m2), chronic diseases, medication and main reflux symptom).
Population selection, inclusion and exclusion criteria: Patient selection was done after the following analysis. Each patients that had reflux symptoms (heartburn and regurgitation) and 8 or more points at the Spanish version of GERD questionnaire validated by Zavala-González et al., underwent an upper videoendoscopy using initially high definition white light and then virtual chromoendoscopy (I-Scan™) in the three different image algorithms. After performing an upper endoscopy completely and reach the line Z, the entire esophagus was evaluated (upper, middle and lower esophagus). If they had any signs of reflux as ulcerative esophagitis, esophageal strictures, Barrett's esophagus or any erosive sign according to Los Angeles classification (Grade A to D), they were classified as GERD patients and were excluded from the protocol. The endoscopies were performed by the same three endoscopist that will carry on the study.
If the esophagus was normal and no changes were seen by these two techniques, they were considered as NERD patients and a pH-impedanciometry was performed as gold standard study, in order to diagnosis reflux disease. GERD diagnosis was considered when there were more than 73 episodes of reflux episodes in 24 hours or acid exposure time (AET) abnormal with ph <4 measured in more than 4,2%of the time over 24 hours.
After this phase, the investigators could discriminate patients that had a normal pH-impedanciometry and no reflux disease from the real NERD patients with reflux disease proven by a positive pH-impedanciometry with symptoms and no lesion.
Two groups were selected. One was the control group and included patients that agreed to be part of the study and for whom we have certainty that they have no GERD (reflux symptoms but negative upper endoscopy with high definition white light or I-Scan and negative Ph-impedanciometry). The other group includes NERD patients with reflux symptoms, a positive Ph-Impedanciometry but a negative upper endoscopy with high definition white light or I-Scan.
Survey: It will be use the Spanish version of the Gastroesophageal Reflux Disease Questionnaire survey, validated in Mexico by Zavala-González et al., but in an Ecuadorian population.
- How often did you have a burning feeling behind your breastbone (heartburn)?
- How often did you have stomach contents (liquid or food) moving upwards to your throat or mouth (regurgitation)?
- How often did you have pain in the center of the upper stomach?
- How often did you have nausea?
- How often did you have difficulty getting a good night's sleep because of your heartburn and/or regurgitation?
- How often did you take additional medication for your heartburn and/or regurgitation, other than what the physician told you to take (such as Tums, Rolaids and Maalox)?
Endoscopic technique: All the patients included in the protocol (NERD group and control group) will be studied by upper endoscopy with Magniview™ scopes and EPK-i7010 processor (OE system™).
The technique involves the use of a distal rubber hood (OE-A58) at the tip of the scope (EG-2990Zi). After reaching the line Z, the four quadrants of the three levels of the esophagus (upper, middle and lower esophagus) will be evaluated in the same way. The cup will contact to the esophageal mucosa and water will be instilled. Initially only the OE system™ will be used (mode 1) If there is no evidence of minimal changes, the optical magnification will be implemented through the actions of a button on the Magniview scope. Finally the OE system™ will be off and only the Magniview™ will be used with white light.
All changes seen will be recorded (by video and pictures) in the specific phase of the study (OE system™ alone, OE system™ with Magniview™ or Magniview™ alone). Finally, biopsies will be taken in both groups (one of each esophagus level randomly and one targeted biopsy to any lesion). The endoscopies will be performed by three endoscopist blind to the group selection and trained on this new technology (all of them with more than 10 procedures).
Mucosal minimal changes will be evaluated as the Sharma et al. classification:
- IPCLs (number, dilatation, and tortuosity). Dilatation of IPCLs will be recognized as a change in the pattern characterized by increased size or caliber of individual IPCLs. Tortuosity is define by the presence of corkscrewing or the twisted nature of individual IPCLs.
- Presence of microerosions (definitive mucosal breaks not visible at standard endoscopy).
- Vascularity at the squamocolumnar junction.
- Presence of columnar island in the distal esophagus.
- Ridge-villous pattern below the squamocolumnar junction characterized by the presence of uniform, longitudinally aligned ridges alternating with a villiform pattern.
Interobserver and Intraobserver Agreement: A data set containing pictures of the three esophagus levels in the three phase of the study (OE system™ alone, OE system™ with Magniview™ or Magniview™ alone) will be presented to three blinded endoscopists, who will confirm or not the findings. Inter- and intraobserver reproducibility will be measured based on comparison of still images between the three investigators. To evaluate the intraobserver agreement each investigator will assess the images three times and the answers will be compared. To evaluate the interobserver agreement all answers between the three investigators will be compared.
Statistical analysis: Baseline characteristics as age, gender, body mass index, symptoms will be compared between case and control group using Chi-square o Fisher Test for categorical variable, and for continuing variables, we will use the Mann-Whitney Test. Diagnosis efficacy will be measured thought sensitive, specificity and accuracy. All the statistical analysis will be performed using SPSS software suite v.22.
Limitations
- Only patients with typical reflux symptoms will participate in the study (heartburn or regurgitation).
- The protocol will be performed in only one center.
- Conditions
- Non Erosive Reflux Disease, GERD
- Being tested
- Optical Enhancement, Optical Enhancement with optical magnification, Optical magnification without Optical enhancement
- Medical subject headings
- Non-Erosive Reflux Disease, Gastroesophageal Reflux
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Optical EnhancementDevice
Also called OE system
A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan)
Optical Enhancement with optical magnificationDevice
Also called OE sytem with optical magnification
A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi)
Optical magnification without Optical enhancementDevice
Also called Optical magnification without OE sytem
A endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement
| Study group | Role | What they receive |
|---|---|---|
| NERD group | (Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a positive ph-impedanciometry for reflux Receives: Device: Optical Enhancement; Device: Optical Enhancement with optical magnification; Device: Optical magnification without Optical enhancement | |
| Control group | (Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a negative ph-impedanciometry for reflux Receives: Device: Optical Enhancement; Device: Optical Enhancement with optical magnification; Device: Optical magnification without Optical enhancement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Digital chromoendoscopy and optical magnification in the diagnosis of intrapapillary loops (IPCLs) in esophagus. Number of participants with increased number of IPCLs, dilatation or tortuosity of IPCLs
Measured: two months
Secondary outcomes (2)
Number of patients in whom the minimal esophageal changes are diagnosed by the digital chromoendoscopy without using the magnification, or with the magnification without using the digital chromoendoscopy or using both.
Measured: two months
Number of patients with increased number, dilatation or tortuosity of the intrapapilary loops on endoscopic image and have a positive biopsy for inflammation of mucosa.
Measured: two months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Oct 2015 (estimated)
- Study startSep 2015
- Primary completionJan 2016
- Study completionJan 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for Non Erosive Reflux DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Carlos A Robles-Medranda, MD, Principal investigator, Ecuadorian Institute of Digestive Diseases
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02575287
- Sponsor's protocol ID
- I-JUN-17-2015
- Status last verified
- Jan 2016
- First submitted
- 9 Sep 2015
- Last updated
- 11 Jan 2016
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943. doi: 10.1111/j.1572-0241.2006.00630.x.
PubMed 16928254Kasap E, Zeybel M, Asik G, Ayhan S, Yuceyar H. Correlation among standard endoscopy, narrow band imaging, and histopathological findings in the diagnosis of nonerosive reflux disease. J Gastrointestin Liver Dis. 2011 Jun;20(2):127-30.
PubMed 21725507Zentilin P, Savarino V, Mastracci L, Spaggiari P, Dulbecco P, Ceppa P, Savarino E, Parodi A, Mansi C, Fiocca R. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol. 2005 Oct;100(10):2299-306. doi: 10.1111/j.1572-0241.2005.50209.x.
PubMed 16181384Kim MS, Choi SR, Roh MH, Lee JH, Jang JS, Kim BG, Kim SO, Han JS, Hsing CT. Efficacy of I-scan endoscopy in the diagnosis of gastroesophageal reflux disease with minimal change. Clin Endosc. 2011 Sep;44(1):27-32. doi: 10.5946/ce.2011.44.1.27. Epub 2011 Sep 30.
PubMed 22741109Zavala-Gonzales MA, Azamar-Jacome AA, Meixueiro-Daza A, Ramos A, J JR, Roesch-Dietlen F, Remes-Troche JM. Validation and diagnostic usefulness of gastroesophageal reflux disease questionnaire in a primary care level in Mexico. J Neurogastroenterol Motil. 2014 Oct 30;20(4):475-82. doi: 10.5056/jnm14014.
PubMed 25273118Kandulski A, Weigt J, Caro C, Jechorek D, Wex T, Malfertheiner P. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1075-81. doi: 10.1016/j.cgh.2014.11.033. Epub 2014 Dec 9.
PubMed 25496815Dent J, Armstrong D, Delaney B, Moayyedi P, Talley NJ, Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut. 2004 May;53 Suppl 4(Suppl 4):iv1-24. doi: 10.1136/gut.2003.034272.
PubMed 15082609Sharma P, Wani S, Bansal A, Hall S, Puli S, Mathur S, Rastogi A. A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology. 2007 Aug;133(2):454-64; quiz 674. doi: 10.1053/j.gastro.2007.06.006. Epub 2007 Jun 8.
PubMed 17681166Kumagai Y, Toi M, Inoue H. Dynamism of tumour vasculature in the early phase of cancer progression: outcomes from oesophageal cancer research. Lancet Oncol. 2002 Oct;3(10):604-10. doi: 10.1016/s1470-2045(02)00874-4.
PubMed 12372722Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999 Aug;45(2):172-80. doi: 10.1136/gut.45.2.172.
PubMed 10403727Neumann H, Fujishiro M, Wilcox CM, Monkemuller K. Present and future perspectives of virtual chromoendoscopy with i-scan and optical enhancement technology. Dig Endosc. 2014 Jan;26 Suppl 1:43-51. doi: 10.1111/den.12190. Epub 2013 Oct 23.
PubMed 24373000Gomes CA Jr, Loucao TS, Carpi G, Catapani WR. A study on the diagnosis of minimal endoscopic lesions in nonerosive reflux esophagitis using computed virtual chromoendoscopy (FICE). Arq Gastroenterol. 2011 Jul-Sep;48(3):167-70. doi: 10.1590/s0004-28032011000300002.
PubMed 21952699
Study at a glance
From the registry record, last updated by the sponsor on 11 Jan 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mucosal and Minimal Injuries Detected Through Digital Chromoendoscopy Using Optical Enhancement System™ Associated to High Definition Plus Optical Magnification in Non Erosive Gastroesophageal Reflux Disease
- ClinicalTrials.gov ID
- NCT02575287
- Acronym / sponsor ID
- I-JUN-17-2015
- Conditions
- Non Erosive Reflux Disease, GERD
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Instituto Ecuatoriano de Enfermedades DigestivasUniversity, hospital or other
- Study start
- Sep 2015
- Primary completion
- Jan 2016 (actual)
- Study completion
- Jan 2016 (actual)
- First posted
- 14 Oct 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
White light endoscopy remains the gold standard technique to evaluate gastrointestinal tract. Gastroesophageal Reflux Disease (GERD) is defined as presence of reflux symptoms (heartburn and regurgitation) associated or not with lesions in esophageal mucosa. Based on findings at videoendoscopy GERD patients can have a complicated reflux disease (erosive esophagitis) or not and be considered as a non erosive reflux disease (NERD). 60% of GERD patients have normal endoscopy (NERD) and requires further studies to achieve a definitive diagnosis. Based on this fact is that the study will be focus on NERD patients.
Recently an image-enhanced endoscopic technology using a pre-processor band-limited light called Optical Enhancement system (OE system™), was developed (Pentax Medical). This new technology combines digital signal processing with optical filters that limit the spectral characteristics of the illumination light. The new innovated optical filters achieve higher overall transmittance by connecting the peaks of the hemoglobin absorption spectrum (415 nm, 540 nm and 570 nm) creating a continuous wavelength spectrum. There are two modes with different OE filters (Mode 1 and Mode 2). Mode 1 is designed to improve visualization of microvessels with a sufficient amount of light, and Mode 2 is designed to improve contrast of white-light observation by bringing the color tone of the overall image closer to that of natural color.
In addition, new scopes has been developed which combines high definition images with optical magnification called Magniview™. These scopes increase the image up to 136 times with a better quality of image than standard scopes without optical zoom. Sharma et al. evaluated esophageal changes in NERD patients using a similar pre-processor filter called Narrow Band Imaging (NBI). They found that a significantly higher proportion of patients with NERD had an increased number, dilation and tortuosity of the microscopic intrapapillary capillary loops (IPCLs), and were considered the best predictors for diagnosing NERD. They used optical chromoendoscopy technology (NBI) associated to magnification scopes (Olympus GIF Q240Z, 115x), but they did not evaluated if the contribution with this technology to the observations found in GERD patients were as a result of the NBI or the magnification scopes. The investigators opinion is that chromoendoscopy is useful but is the magnification what makes up the difference.
Detailed description
Sharma et al. described in detail the changes of the intrapapillary capillaries seen with reflux inflammation. In the normal esophageal mucosa, submucosa all vessels are connected to the arborescent vascular network. Intrapapillary capillaries arise from the fourth branch of the arborescent vessels into the epithelial papillae and form single loops called IPCLs. It has been shown that IPCLs dilate and elongate along with an increase in the number and density of arborescent vessels in mucosal cancer. These changes are similar to those observed in inflammation.
Estimated enrollment: 100 patients (NERD group: 50 patients and control group: 50 patients)
Study design: This is an observational and analytical cross-section, population - based survey study, with prospective case collection, non-randomized and simple blind, performed in a Tertiary Academic Center.
Study Design
- Allocation: Non randomized, simple blind
- Endpoint Classification: Efficacy
- Intervention Model: Non interventional
- Primary Purpose: Diagnosis
Setting: Instituto Ecuatoriano de Enfermedades Digestivas (IECED), OmniHospital Academic Tertiary Center. We will include patients from September 2015 to November 2015. Patients will be recruited from the gastroenterology unit (IECED). The study protocol and consent form has been approved by the IRB and will be conducted according to the declaration of Helsinki. Patients will sign an informed consent and answer a questionnaire that includes constitutional data (sex, age, weight (Kg), height (m), BMI (Kg/m2), chronic diseases, medication and main reflux symptom).
Population selection, inclusion and exclusion criteria: Patient selection was done after the following analysis. Each patients that had reflux symptoms (heartburn and regurgitation) and 8 or more points at the Spanish version of GERD questionnaire validated by Zavala-González et al., underwent an upper videoendoscopy using initially high definition white light and then virtual chromoendoscopy (I-Scan™) in the three different image algorithms. After performing an upper endoscopy completely and reach the line Z, the entire esophagus was evaluated (upper, middle and lower esophagus). If they had any signs of reflux as ulcerative esophagitis, esophageal strictures, Barrett's esophagus or any erosive sign according to Los Angeles classification (Grade A to D), they were classified as GERD patients and were excluded from the protocol. The endoscopies were performed by the same three endoscopist that will carry on the study.
If the esophagus was normal and no changes were seen by these two techniques, they were considered as NERD patients and a pH-impedanciometry was performed as gold standard study, in order to diagnosis reflux disease. GERD diagnosis was considered when there were more than 73 episodes of reflux episodes in 24 hours or acid exposure time (AET) abnormal with ph <4 measured in more than 4,2%of the time over 24 hours.
After this phase, the investigators could discriminate patients that had a normal pH-impedanciometry and no reflux disease from the real NERD patients with reflux disease proven by a positive pH-impedanciometry with symptoms and no lesion.
Two groups were selected. One was the control group and included patients that agreed to be part of the study and for whom we have certainty that they have no GERD (reflux symptoms but negative upper endoscopy with high definition white light or I-Scan and negative Ph-impedanciometry). The other group includes NERD patients with reflux symptoms, a positive Ph-Impedanciometry but a negative upper endoscopy with high definition white light or I-Scan.
Survey: It will be use the Spanish version of the Gastroesophageal Reflux Disease Questionnaire survey, validated in Mexico by Zavala-González et al., but in an Ecuadorian population.
- How often did you have a burning feeling behind your breastbone (heartburn)?
- How often did you have stomach contents (liquid or food) moving upwards to your throat or mouth (regurgitation)?
- How often did you have pain in the center of the upper stomach?
- How often did you have nausea?
- How often did you have difficulty getting a good night's sleep because of your heartburn and/or regurgitation?
- How often did you take additional medication for your heartburn and/or regurgitation, other than what the physician told you to take (such as Tums, Rolaids and Maalox)?
Endoscopic technique: All the patients included in the protocol (NERD group and control group) will be studied by upper endoscopy with Magniview™ scopes and EPK-i7010 processor (OE system™).
The technique involves the use of a distal rubber hood (OE-A58) at the tip of the scope (EG-2990Zi). After reaching the line Z, the four quadrants of the three levels of the esophagus (upper, middle and lower esophagus) will be evaluated in the same way. The cup will contact to the esophageal mucosa and water will be instilled. Initially only the OE system™ will be used (mode 1) If there is no evidence of minimal changes, the optical magnification will be implemented through the actions of a button on the Magniview scope. Finally the OE system™ will be off and only the Magniview™ will be used with white light.
All changes seen will be recorded (by video and pictures) in the specific phase of the study (OE system™ alone, OE system™ with Magniview™ or Magniview™ alone). Finally, biopsies will be taken in both groups (one of each esophagus level randomly and one targeted biopsy to any lesion). The endoscopies will be performed by three endoscopist blind to the group selection and trained on this new technology (all of them with more than 10 procedures).
Mucosal minimal changes will be evaluated as the Sharma et al. classification:
- IPCLs (number, dilatation, and tortuosity). Dilatation of IPCLs will be recognized as a change in the pattern characterized by increased size or caliber of individual IPCLs. Tortuosity is define by the presence of corkscrewing or the twisted nature of individual IPCLs.
- Presence of microerosions (definitive mucosal breaks not visible at standard endoscopy).
- Vascularity at the squamocolumnar junction.
- Presence of columnar island in the distal esophagus.
- Ridge-villous pattern below the squamocolumnar junction characterized by the presence of uniform, longitudinally aligned ridges alternating with a villiform pattern.
Interobserver and Intraobserver Agreement: A data set containing pictures of the three esophagus levels in the three phase of the study (OE system™ alone, OE system™ with Magniview™ or Magniview™ alone) will be presented to three blinded endoscopists, who will confirm or not the findings. Inter- and intraobserver reproducibility will be measured based on comparison of still images between the three investigators. To evaluate the intraobserver agreement each investigator will assess the images three times and the answers will be compared. To evaluate the interobserver agreement all answers between the three investigators will be compared.
Statistical analysis: Baseline characteristics as age, gender, body mass index, symptoms will be compared between case and control group using Chi-square o Fisher Test for categorical variable, and for continuing variables, we will use the Mann-Whitney Test. Diagnosis efficacy will be measured thought sensitive, specificity and accuracy. All the statistical analysis will be performed using SPSS software suite v.22.
Limitations
- Only patients with typical reflux symptoms will participate in the study (heartburn or regurgitation).
- The protocol will be performed in only one center.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| NERD group | – | Device: Optical Enhancement, Device: Optical Enhancement with optical magnification, Device: Optical magnification without Optical enhancement(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a positive ph-impedanciometry for reflux |
| Control group | – | Device: Optical Enhancement, Device: Optical Enhancement with optical magnification, Device: Optical magnification without Optical enhancement(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a negative ph-impedanciometry for reflux |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients that had reflux symptoms (heartburn and regurgitation) and 8 or more points at the Spanish version of GERD questionnaire validated by Zavala-González et al. underwent an upper videoendoscopy using initially high definition white light and then digital chromoendoscopy (I-Scan™) in the three different image algorithms. If the esophagus was normal and no changes were seen by these two techniques, they were considered as NERD patients and a pH-impedanciometry was performed as gold standard study, in order to diagnosis reflux disease. We considered a GERD diagnosis with more than 73 episodes of reflux in 24 hours or acid exposure time abnormal with ph<4 measured in more than 4,2%of the time over 24 hours.
Key inclusion criteria (3 listed)
- Above 18 years old patients
- Who agree to participate in the study
- Patients with reflux symptoms (heartburn and regurgitation), with8 or more points at the GERD questionnaire and no evidence of ulcerative esophagitis, esophageal strictures, Barrett's esophagus or any erosive sign according to Los Angeles classification (Grade A to D) in the upper endoscopy using white light nor I-Scan™
Key exclusion criteria (10 listed)
- Patients with ulcerative esophagitis, esophageal strictures, Barrett's esophagus or any erosive sign according to Los Angeles classification (Grade A to D)
- Patients with medical history of any kind of esophagitis (including actinic, caustic or eosinophilic), achalasia.
- Esophageal varices
- Patients with evidence of cancer or mass lesion in the esophagus
- Protons bump inhibitor consumption for at least 3 weeks before endoscopy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Optical EnhancementAlso: OE systemA endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan) | Device | Control group, NERD group |
| Optical Enhancement with optical magnificationAlso: OE sytem with optical magnificationA endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi) | Device | Control group, NERD group |
| Optical magnification without Optical enhancementAlso: Optical magnification without OE sytemA endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement | Device | Control group, NERD group |
Primary outcome
Digital chromoendoscopy and optical magnification in the diagnosis of intrapapillary loops (IPCLs) in esophagus. Number of participants with increased number of IPCLs, dilatation or tortuosity of IPCLs
Time frame: two months
2 secondary outcomes
Number of patients in whom the minimal esophageal changes are diagnosed by the digital chromoendoscopy without using the magnification, or with the magnification without using the digital chromoendoscopy or using both.
Time frame: two months
Number of patients with increased number, dilatation or tortuosity of the intrapapilary loops on endoscopic image and have a positive biopsy for inflammation of mucosa.
Time frame: two months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jan 2016.
- Background: PubMed 16928254Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943. doi: 10.1111/j.1572-0241.2006.00630.x.
- Background: PubMed 21725507Kasap E, Zeybel M, Asik G, Ayhan S, Yuceyar H. Correlation among standard endoscopy, narrow band imaging, and histopathological findings in the diagnosis of nonerosive reflux disease. J Gastrointestin Liver Dis. 2011 Jun;20(2):127-30.
- Background: PubMed 16181384Zentilin P, Savarino V, Mastracci L, Spaggiari P, Dulbecco P, Ceppa P, Savarino E, Parodi A, Mansi C, Fiocca R. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol. 2005 Oct;100(10):2299-306. doi: 10.1111/j.1572-0241.2005.50209.x.
- Background: PubMed 22741109Kim MS, Choi SR, Roh MH, Lee JH, Jang JS, Kim BG, Kim SO, Han JS, Hsing CT. Efficacy of I-scan endoscopy in the diagnosis of gastroesophageal reflux disease with minimal change. Clin Endosc. 2011 Sep;44(1):27-32. doi: 10.5946/ce.2011.44.1.27. Epub 2011 Sep 30.
- Background: PubMed 25273118Zavala-Gonzales MA, Azamar-Jacome AA, Meixueiro-Daza A, Ramos A, J JR, Roesch-Dietlen F, Remes-Troche JM. Validation and diagnostic usefulness of gastroesophageal reflux disease questionnaire in a primary care level in Mexico. J Neurogastroenterol Motil. 2014 Oct 30;20(4):475-82. doi: 10.5056/jnm14014.
- Background: PubMed 25496815Kandulski A, Weigt J, Caro C, Jechorek D, Wex T, Malfertheiner P. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1075-81. doi: 10.1016/j.cgh.2014.11.033. Epub 2014 Dec 9.
- Background: PubMed 15082609Dent J, Armstrong D, Delaney B, Moayyedi P, Talley NJ, Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut. 2004 May;53 Suppl 4(Suppl 4):iv1-24. doi: 10.1136/gut.2003.034272.
- Background: PubMed 17681166Sharma P, Wani S, Bansal A, Hall S, Puli S, Mathur S, Rastogi A. A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology. 2007 Aug;133(2):454-64; quiz 674. doi: 10.1053/j.gastro.2007.06.006. Epub 2007 Jun 8.
- Background: PubMed 12372722Kumagai Y, Toi M, Inoue H. Dynamism of tumour vasculature in the early phase of cancer progression: outcomes from oesophageal cancer research. Lancet Oncol. 2002 Oct;3(10):604-10. doi: 10.1016/s1470-2045(02)00874-4.
- Background: PubMed 10403727Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999 Aug;45(2):172-80. doi: 10.1136/gut.45.2.172.
- Background: PubMed 24373000Neumann H, Fujishiro M, Wilcox CM, Monkemuller K. Present and future perspectives of virtual chromoendoscopy with i-scan and optical enhancement technology. Dig Endosc. 2014 Jan;26 Suppl 1:43-51. doi: 10.1111/den.12190. Epub 2013 Oct 23.
- Results publication: PubMed 21952699Gomes CA Jr, Loucao TS, Carpi G, Catapani WR. A study on the diagnosis of minimal endoscopic lesions in nonerosive reflux esophagitis using computed virtual chromoendoscopy (FICE). Arq Gastroenterol. 2011 Jul-Sep;48(3):167-70. doi: 10.1590/s0004-28032011000300002.
Related trials for Non Erosive Reflux Disease
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks
Symptomatic Non-erosive Gastroesophageal Reflux Disease
RecruitingObservational study
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
Erosive Esophagitis, Heartburn
Not yet recruiting
Mirgeal® Gel as Add-on Therapy to Esomeprazole in Adults With Non-Erosive Gastroesophageal Reflux Disease
Non-Erosive Gastroesophageal Reflux Disease (NERD)
Not yet recruitingPhase 3
Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis
Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)
Recruiting
QUality of Sleep Improvement With Evening Topical Therapy for Non-Erosive Gastroesophageal Reflux Disease (The QUIET Trial)
Nocturnal Symptoms of GERD, Sleep Disorders in GERD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carlos A Robles-Medranda, MD principal investigator
Ecuadorian Institute of Digestive Diseases
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Non Erosive Reflux Disease and GERD, run by Instituto Ecuatoriano de Enfermedades Digestivas at 1 site in Ecuador.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jan 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ecuador. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Digital chromoendoscopy and optical magnification in the diagnosis of intrapapillary loops (IPCLs) in esophagus. Number of participants with increased number of IPCLs, dilatation or tortuosity of IPCLs (time frame: two months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02575287, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jan 2016.